Psoriasis Clinical Trial
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
Subjects must have psoriatic lesions measuring protocol specific BSA
Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
Pustular psoriasis or erythroderma
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Fridley Minnesota, 55432, United States
Rochester New York, 14623, United States
Austin Texas, 78759, United States
College Station Texas, 77840, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.